The NCPE are seeking input from Patient Organisations for our appraisal of tucatinib (Tukysa) in combination with trastuzumab and capecitabine for adult patients with HER2-positive locally advanced/metastatic breast cancer who have received ..(1/2)

Great 🚨 news for patients with #HER2 (+) #ERBB2 amp BTC #BiliaryTractCancer Novel Tx options #tucatinib #trastuzumab #zanidatamab #ASCO23 congrats 🎉🎊 for the authors!

#HER2CLIMB02 trial
Important study in brain mets
#tucatinib #HER2positive #aBC #SABCS23
SABCS

T:👉Yeni faz 2 çalışması, daha önce tedavi edilmiş safra yolu kanseri hastalarında Tucatinib ve trastuzumab'ın klinik etkinliğini gösterdi (objektif yanıt oranını %46,7 ). *

Bu sonuç, daha büyük çalışma ile doğrulanma ihtiyacı hissetse de HER2 pozitif safra yolu kanserleri için

HER2CLIMB-02 T-DM1 +/- Tucatinib in 2nd line. 460pts randomized.
44% had CNS Mets, of which 50% had active brain Mets
📌 ITT pop- improvement in PFS 9.5mos vs 7.4mos
📌 subgroup of pts with CNS nets- improvement in PFS 7.8mo vs. 5.7mo @oncoalert SABCS #sabcs

Tucatinib plus TDM1 vs TDm1 alone
. Her2climb02 . Useful PFS benifit , especially in patients with brain mets. No OS benfit. Hr 1.23 . Can be used in those with Brain mets . SABCS OncoAlert #SABCS23

Excited to initiate the Mountaineer-03 study offering Tucatinib and Trastuzumab in combination with mFOLFOX6 vs SOC in first line setting for HER2+ mCRC. PI of the study is Dr Brian Healey Bird #HER2 + #colorectalcancer #mCRC UCC Cancer Trials Group CRF-UCC Cancer Research @UCC CancerTrialsIreland 🌈

#WCGIC2023
💊 Emerging 🎯 in #GI cancer
🪑Dr. Van Cutsem + Dr. Carnero
🗣️Valentina Gambardella
🎯 HER2
✔️ T-DxT for #GastricCancer #DestinyGastric01 2nd line #FDA --> ⏳ #DestinyGastric02
✔️Trastuzumab + tucatinib for #CCR #MOUNTAINEER
✔️Zanidatamab #BiliaryTract #HERIZONBTC01
World Congress on Gastrointestinal Cancer

Is SRS WITH tucatinib for brain mets safe?
Based on this study, Yes.
· 135 lesions SRS
· 4% symptomatic radiation necrosis
rdcu.be/dihvn

Tucatinib+trastuzumab = new SOC for pts #HER2 + #colorectalcancer
Success story of Academic-Industry Collab from IIT Academic & Community Cancer Research United --> promising results --> transfer IND to @SeagenGlobal with registration intent --> FDA Oncology approval in Jan 23
thelancet.com/journals/lanon…

Current treatment algorithm for metastatic her2 postive breast cancer
And where can we fit tucatinib plus TDM1 ? Intresting. SABCS #SABCS23 OncoAlert

Great data HER2CLIMB-02 SABCS T-DM1 + Tucatinib improves PFS, ORR in pts with brain mets! Q on the sequencing of T-DXd and T-DM1 + Tucatinib in pts with brain mets still remains! OncoAlert Roswell Park Hematology/Oncology Fellowship #SABCS23 #SaraHurvitz

7 Kasım 2023 Salı günü saat 12.30 'da Ali Furkan KIDIL'ın  ' HER2-Selective and Reversible Tyrosine Kinase updates Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer ' sunumuna katılımlarınızı bekliyoruz.
#universitemdeu

Tucatinib/trastuzumab in 2nd line metastatic HER2 + biliary tract cancer very positive in small phase 2 study #ASCO23

Summary of 5 new drugs/indications in GI malignancies that were FDA Oncology U.S. FDA approved in 2023:

- #Tucatinib - Mountaineer
- #TAS102 + #Bevacizumab - Sunlight
- #Pembro + Cis/Gem - KN966
- #Fruquintinib - FRESCO2
- #Pembro + Chemo - KN859

#OncTwitter #gism #crcsm

At #SABCS23 results of HER2CLIMB-02, testing T-DM1 + tucatinib vs. T-DM1 + placebo in pretreated HER2+ mBC
➡️statistically significant ⬆️ of PFS (9.5 vs. 7.4 mos)
➡️ PFS benefit in pts with brain mets 🧠 (7.8 vs. 5.7 mos)
OncoAlert

SGNTUC-019 PhII basket of tucatinib + trastuzumab for pretreated w/>1 prior line #HER2 + adv BTC confirmed ORR 46.7% (1 CR, 13 PRs), DOR 6 mos, and median OS 15.5 mos #ASCO23 OncoAlert

HER2climb02 significant improvement in PFS favouring tucatinib +TDM1 mainly in brain mets population #SABCS23 SOLTI #cancerresearch ESMO Open ASCO SABCS

Tucatinib and trastuzumab in HER2+ biliary tract cancer:
🔹️46.7% ORR, 1 CR
🔹️Median DoR: 6 months
🔹️Median PFS and OS: 5.5 and 15.5 months, respectively.
🔹️Chemo-free regimen
Very encouraging!
#ASCO23 #hpbcsm #CancerResearch

T-DM1 plus tucatinib is a positive trial. Look forward to data and brain Mets population!

Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival #bcsm investor.seagen.com/press-releases…